About ReveraGen
ReveraGen is a company based in Rockville (United States) founded in 2008 by Kanneboyina Nagaraju. ReveraGen offers products and services including Vamorolone. ReveraGen operates in a competitive market with competitors including Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
- Headquarter Rockville, United States
- Founders Kanneboyina Nagaraju
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Reveragen Biopharma, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$1.2 M (USD), Grant
Sep 27, 2021
-
Investors
NIH
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ReveraGen
ReveraGen offers a comprehensive portfolio of products and services, including Vamorolone.
Drug designed to treat Duchenne Muscular Dystrophy with improved safety.
People of ReveraGen
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of ReveraGen
Investors in ReveraGen
ReveraGen has secured backing from 10 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
The U.S. Food and Drug Administration is tasked with regulating food, drugs, and medical products.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for ReveraGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ReveraGen
Investment portfolio details for ReveraGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ReveraGen
Detailed financials for ReveraGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Reveragen Comparisons
Peer comparison for ReveraGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ReveraGen
ReveraGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for rare genetic diseases
|
|
| Locked | Locked | Locked |
Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema.
|
Detailed competitors of ReveraGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Reveragen
Complete news archive for ReveraGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReveraGen
ReveraGen was founded in 2008 and raised its 1st funding round 2 years after it was founded.
ReveraGen is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Eric Hoffman is the current CEO of ReveraGen.
ReveraGen was founded in 2008 in Rockville, United States, as a drug development company focused on neuromuscular diseases. Proprietary therapeutic products, including the lead candidate Vamorolonea steroidal anti-inflammatoryare discovered and developed for conditions such as Duchenne muscular dystrophy. Operations center on advancing treatments through clinical stages, with emphasis on innovative steroid formulations for patient care in the biotechnology sector.
ReveraGen's top competitors include Alnylam, UniQure and BioMarin Pharmaceutical.
ReveraGen offers Vamorolone.
ReveraGen has 10 investors. Key investors include NIH, HHS, European Union, U.S. Food and Drug Administration, and Duchenne UK.